|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/48 | (2006.01) |
| A61K 31/00 | (2013.01) | ||
| A61P 3/00 | (2006.01) | ||
| A61P 17/02 | (2018.01) | ||
| A61P 7/02 | (2006.01) | ||
| A61P 3/00 | (2018.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 7/02 | (2018.01) | ||
| A61P 17/02 | (2006.01) | ||
| A61P 9/00 | (2018.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61K 38/484 | (2013.01) |
| (11) | Number of the document | 3641888 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18821458.9 |
| Date of filing the European patent application | 2018-06-22 | |
| (97) | Date of publication of the European application | 2020-04-29 |
| (45) | Date of publication and mention of the grant of the patent | 2023-10-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2018/000655 |
| Date | 2018-06-22 |
| (87) | Number | WO 2018/234861 |
| Date | 2018-12-27 |
| (30) | Number | Date | Country code |
| 201762523901 P | 2017-06-23 | US |
| (72) |
GAGNON, Lyne , CA
GROUIX, Brigitte , CA
LAURIN, Pierre , CA
|
| (73) |
Kedrion Biopharma Inc. ,
400 Kelby Street, Suite 1200, Fort Lee, NJ 07024,
US
|
| (54) | PLASMINOGEN TREATMENT OF CONDITIONS ASSOCIATED WITH PAI-1 OVEREXPRESSION |
| PLASMINOGEN TREATMENT OF CONDITIONS ASSOCIATED WITH PAI-1 OVEREXPRESSION |